

Date: October 09, 2026

Ref. No.: KDL/SE/55/2026-27

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001. Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
---	---

Dear Sir/Madam,

Sub: Intimation of receipt of In-principle Approval letter from BSE Limited for issue of 16,21,000 convertible warrants on Preferential basis in terms of Regulation 28(1) to the Promoter and Promoter Group of the Company

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 "SEBI (LODR)", and in continuation of our intimation dated October 08, 2026 (Ref. No. KDL/SE/053/2026-27) regarding receipt of In-principle Approval from BSE Limited and National Stock Exchange of India Limited for issue of 16,21,000 warrants convertible into 16,21,000 Equity shares of face value Rs. 5/- each at an issue price of Rs. 566/- each to the Promoter and Promoter Group of the Company on preferential basis in terms of Regulation 28(1), we wish to inform you that the Company has now received the corrected In-principle Approval letter from BSE Limited vide letter no. LOD/PREF/PB/FIP/908/2026-27, rectifying the factual errors in the earlier letter.

A copy of the corrected in-principle approval letter received from BSE Limited is enclosed herewith.

The above information will also be available on the website of the Company at <https://krsnaadiagnostics.com/investors/>.

You are requested to take the above information on record.

Thanking you,
Yours sincerely

For Krsnaa Diagnostics Limited

Sujoy
Sudipta
Bose

Sujoy Sudipta Bose

Company Secretary & Compliance Officer

Encl: as above

Digitally signed by Sujoy Sudipta Bose
DN: cn=Sujoy Sudipta Bose, o=Krsnaa Diagnostics Limited, c=IN, email=sujoy.sudipta.bose@krsnaadiagnostics.com, serial=453328, version=1
D: 2026.10.09 16:11:57 +05'30'
email=sujoy.sudipta.bose@krsnaadiagnostics.com, cn=Sujoy Sudipta Bose
Date: 2026.10.09 16:11:57 +05'30'

LOD/PREF/PB/FIP/908/2026-27

October 07, 2026

To,
The Company Secretary,
Krsnaa Diagnostics Ltd
S. No. 243/A, Hissa No.6, CTS No. 4519, 4519/1,
Near Chinchwad Station, Chinchwad,
Taluka - Haveli Pune 411019

Re: 'In-principle' approval under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Dear Sir/Madam,

We refer to your application seeking our **"In-principal approval for the issue of 16,21,000 warrants convertible into 16,21,000 equity shares of Rs. 5/- each at price not less than Rs. 566/- each to promoters on preferential basis"**.

The Exchange hereby grants its 'in-principle' approval for the aforesaid issue. This 'in-principle' approval should not be construed as our approval for listing of aforesaid security, and you are required to duly and separately comply with the requirements in respect thereof.

You are advised to ensure that the issue and allotment of securities is strictly in accordance with the provisions of the Companies Act, 2013, Securities Contracts (Regulation) Act, 1956, the Securities and Exchange Board of India Act, 1992, the Depositories Act, 1996 including the Rules, Regulations, Guidelines, etc. made there under, Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR Regulations), the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (LODR Regulations) and the Listing Agreement signed with us. In addition, you shall also obtain such statutory and other approvals as are required for the purpose.

Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention to provisions of Chapter V of SEBI (ICDR) Regulations. In this regard,

- a) Company is advised to obtain an undertaking from the allottee(s) confirming that they shall not do intra-day trading in the scrip of the company or any sale in the scrip of the company till the allotment date of the security as required under SEBI (ICDR) Regulations.

- b) The company may note that the responsibility/onus is solely on the Issuer company to verify the above (a) and ensure compliance with applicable provisions including Regulation 167(6) of SEBI ICDR regulations, 2018.
- c) The company may also note that any non-compliances, if observed by the exchanges post the undertaking and verification by the Issuer company may impact the listing of such shares.

On allotment of securities pursuant to this 'in principle' approval you are required to make a listing application without delay, with applicable fees, in terms of Regulation 14 of the LODR Regulations and comply with the post issue formalities.

Listing application and the checklist for post issue listing formalities can be downloaded from the link: <https://www.bseindia.com/static/about/downloads.aspx>. Further, it should be noted by Depositories and the Company that in case of allotment of Convertible Securities, there would be automatic release of excess lock-in period of Pre-Preferential Holding of allottees by Depositories in compliance with SEBI(ICDR) Regulations, 2018 without requirement of any NOC by the Exchange.

In addition to above, the company should note that as per Schedule XIX – Para (2) of ICDR Regulations and as specified in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, "the issuer or the issuing company, as the case may be, shall, make an application for listing, within twenty days from the date of allotment, to one or more recognized stock exchange(s)" along with the documents specified by stock exchange(s) from time to time. Any Non-compliance with the above requirement will attract, the fine as mentioned in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023.

The Exchange reserves its right to withdraw this 'in-principle' approval at any stage if the information submitted to the Exchange is found to be incomplete/ incorrect/ misleading/ false or if it contravenes any Rules, Bye-laws and Regulations of the Exchange, LODR Regulations, ICDR Regulations and Guidelines/ Regulations issued by any statutory authorities etc.

Yours faithfully,



Nitinkumar Pujari
Assistant Vice President



Prachi Babadi
Manager